Education Featured Article
February 20, 2013
Pearson Gives Education Startups a Boost
By Robbie Pleasant, TMCnet Contributor
Pearson is a landmark for education, and it’s ready to offer its experience to startups that want to do the same. The Pearson Catalyst is a startup incubator program, made to find the education startups it feels shares its commitment to education, and help it break into the global market.
The Pearson Catalyst program seeks tech-centric startup teams, three years old or younger, with products ready for the market. Preferably their products will complement or enhance a Pearson brand, of course, but that’s just good business. It will then help up to 10 teams for at least three months, accelerating them and getting their products to the market faster and with a bigger splash.
The startups selected by Pearson will receive a number of benefits and assistance to help get started. This includes access to Pearson’s executives and product experts for help and advice, as well as potential sponsorship. They’ll also receive up to $10,000 for travel expenses and similar costs, focusing their funds on creating the best products they can.
They will then be able to present at a Pearson demo day to executives and technology leaders, potentially winning over more sponsors.
“Pearson Catalyst reflects our desire to be more open and work with forward thinking companies to solve the biggest challenges in global education,” stated Diana Stepner, Head of Future Technologies at Pearson. “We believe the future of learning is digital, personal and driven by data - and bringing together Pearson and startups is the perfect combination to build the best future of education today.”
A company focused on education technology knows the importance of getting assistance and help to get started. As such, the Pearson Catalyst program should prove very helpful for startups looking to get started in education technology, but just need a little help to get off the ground.
Interested startups can apply now, and Pearson can help them help the world.
Edited by Braden Becker
LATEST EDUCATION NEWS
Tyrogenex X-82 Poster Presentation at the 2015 American Society for Clinical Oncology (ASCO) Annual Meeting
Kolltan Pharmaceuticals Announces Presentation of KTN3379 Interim Phase 1b Data at 2015 American Society of Clinical Oncology Annual Meeting
Acelarin® achieves very high disease control rates in patients with advanced gynaecological cancers in a Phase I/II setting
Ground-breaking Final Results of the First in Human Phase I/II Study with Acelarin in Advanced Solid Tumours
Studies Presented at 2015 ASCO Meeting Demonstrate Predictive Power of bioTheranostics' Breast Cancer Index? Molecular Test in Endocrine Therapy Decisions
Updated Positive Results from Two Trials of Cobimetinib in Combination with Vemurafenib for the Treatment of Patients with Advanced Melanoma Presented at 2015 ASCO Annual Meeting
Updated Data Showed Genentech's Investigational Combination of Cobimetinib and Zelboraf (Vemurafenib) Helps People With Advanced Melanoma Live for a Year Without Their Disease Worsening
Genentech's Gazyva® Extended the Time People With Refractory Indolent Non-Hodgkin's Lymphoma Lived Without Their Disease Worsening